mRNA-AIL-111 LNP platform

Model: AIL-111 LNP

Booth No: M534

Characteristic

1. Proprietary AIL-111 Platform: A patent-pending ionizable lipid driving a next-generation mRNA-LNP system with high translational potential.
2. Excellent Safety Profile: Demonstrates outstanding tolerability with zero mortality or severe toxicity in multi-dose studies.
3. Current focus on personalized cancer vaccines: Using tumor neoantigen mRNA delivery as the primary development direction.
4. Robust Immunogenicity: Induces highly reproducible, neoantigen-specific T-cell responses in CT26 and MC38 models.
5. Proven Tumor Suppression: Achieves significant tumor growth inhibition with a simple 2-dose IV regimen (CT26 model).

Menu

mRNA-AIL-111 LNP platform

Characteristic

Other Products

Products you may be interested in

Highest Rated Products